2. Agenda
Vitamin D a
global issue
Vitamin D 101
Vitamin D in
skeletal Health
(MBD)
How to treat
Whom to
screen
Extraskeletal
benefits (or
myths?!)
Take-home
Messages
3. Vitamin D deficiency and
insufficiency is a global health
problem
• Vitamin D deficiency is a common
global issue.
• About 1 billion people worldwide have
vitamin D deficiency
• 50% of the population has vitamin D
insufficiency.
J Pharmacol Pharmacother , 2012 Apr;3(2):118-26.
4. Status of vitamin D among Egyptian population
164
420
245
263
1092
1357
1447
544
606
3954
Severe deficiency (<10)
Moderate def. (10–20)
Insufficient (20–30)
Normal (>30)
Total
males females
30.1%
36.9 %
15.6%
17.2%
n= 5046
Endocrine Abstracts (2019) 63 P473 | DOI: 10.1530/endoabs.63.P473 Calcium and Bone 2
5. Definitions of
Vitamin D Deficiency
• No broad consensus on definition of vitamin D deficiency.
• Different organizations have slightly different definitions,
based on serum levels of 25 (OH)D.
Mayo Clin Proc 2010; 85:752-758.
IOM (Institute of Medicine). 2011 Dietary Reference Intakes for Calcium and Vitamin D.
J Clin Endocrinol Metab 2011; 96:1911-30
Endocr Pract. 2016;22(Suppl 4):1-42.
6. What is Vitamin D?
• Vitamin D is a fat-soluble vitamin
• It is involved in the regulation of
calcium homeostasis and bone
health.
• Vitamin D need various steps of
activation to be utilized
7. Sources of Vitamin D
Being exposed to the
sun.
Through the foods
you eat.
Through nutritional
supplements.
8. Daily requirements
Life Stage Recommended Amount
Birth to 12 months 10 mcg (400 IU)
Children 1–13 years 15 mcg (600 IU)
Teens 14–18 years 15 mcg (600 IU)
Adults 19–70 years 15 mcg (600 IU)
Adults 71 years and older 20 mcg (800 IU)
Pregnant and breastfeeding teens and women 15 mcg (600 IU)
https://ods.od.nih.gov/factsheets/VitaminD-Consumer/
9. Minimal amounts of vitamin D
in human breast milk
• The American Academy of Pediatrics
recommends vitamin D supplementation
starting at age 2 months for infants fed
exclusively with breast milk.
Pediatrics. 2003 Apr. 111(4 Pt 1):908-10.
10. Consequences
of Vitamin D
Deficiency
Severe and prolonged
deficiency → bone
mineralization diseases (MBD)
Vitamin D deficiency →
abnormalities in Ca, Po4, and
bone metabolism.
JAMA. 2021;325(14):1436-1442.
11. Consequences of Vitamin D Deficiency
• Vitamin D deficiency has also been associated with fractures, falls, functional
limitations, some types of cancer, diabetes, cardiovascular disease, and
depression. However, the U.S. Preventive Services Task Force notes that,
“Inadequate evidence on the benefit of treatment of asymptomatic vitamin D
deficiency on other outcomes, including falls, cancer, cardiovascular events,
depression, infection, or physical functioning.”
JAMA. 2021;325(14):1436-1442.
12. Symptoms of
vitamin D
deficiency
• Often asymptomatic.
• Severe or prolonged deficiency may
cause:
Bone Pain and tenderness
Falls and impaired physical
function
Muscle aches and weakness
Symmetric low back pain (in
women)
Bordelon P et al. Recogni7on and management of vitamin D deficiency. Am Fam Phys 2009; 80:841-846.
13. Vitamin D and
Bone Health
• Maximum calcium absorption occurs at levels of
(25[OH]D) greater than 32 ng/mL.
• Vitamin D also enhances the absorption of
phosphorus from the distal small bowel.
• Ca + Po-
4 = proper mineralization
• It is also involved in maturation of osteoclasts,
which resorb calcium from the bones.
Journal of the American College of Nutrition 2003, 22 (2): 142-6
14. Which Vitamin D
• The term vitamin D = vitamin
D2 or vitamin D3.
• Vitamin D3 = cholecalciferol
(made in the skin or obtained
in the diet from fatty fish).
• Vitamin D2 = ergocalciferol
(obtained from irradiated fungi,
such as yeast or mushroom).
• Both are used to supplement
food products or in
multivitamins.
J Clin Endocrinol Metab. 2004 Nov. 89(11):5387-91.
Am J Clin Nutr. 1998 Oct. 68(4):854-8.
15. Vitamin D2 and Vitamin D3
• Past studies suggested that vitamin D3 may be more
effective than vitamin D2 in establishing normal vitamin
D stores.
• However, a study by Holick and colleagues
demonstrated that vitamin D2 and vitamin D3 appear to
be equipotent in raising 25(OH)D concentrations when
they are given in daily doses of 1000 IU.
• Some prefer vitamin D3 over vitamin D2, it’s Ok
J Clin Endocrinol Metab. 2004 Nov. 89(11):5387-91.
Am J Clin Nutr. 1998 Oct. 68(4):854-8.
16. The main
problem is the
bone health
• Metabolic Bone disease (MBD) especially rickets
or osteomalacia
17. Metabolic bone disease (MBD)
• MBD, any of several diseases that cause various abnormalities
or deformities of bone
• Examples of MBD include osteoporosis, rickets/osteomalacia,
osteogenesis imperfecta, marble bone
disease (osteopetrosis), Paget disease of bone, and fibrous
dysplasia.
18. Osteomalacia
Several different disorders cause osteomalacia via mechanisms
that result in hypocalcemia, hypophosphatemia, or direct
inhibition of the mineralization process.
Osteomalacia is a disorder of bone, characterized by decreased
mineralization of newly formed osteoid at sites of bone turnover.
19. Poor mineralization
• Failure to replace the turnover of Ca and P in bone
matrix → bone becomes demineralized
• The bony substance becomes replaced by soft osteoid
tissue
• It is mainly a qualitative bone defect.
• There is, unlike osteoporosis, a decline in the ratio of
mineralized bone to matrix.
25. 2ry
hyperparathyroidism
• The most common
cause is vitamin D
deficiency
• It is the combination of
calcium loss from bone
and phosphate
depletion that leads to
impaired bone
mineralization.
CaSR
26. The classification of osteomalacia
1. Hypocalcemic osteomalacia
• Vitamin D deficiency = موجود مش
• Pseudovitamin D deficiency = شغال مش
2. Hypophosphatemic osteomalacia
3. Osteomalacia with normal bone homeostasis
= Defective mineralization
27. The
classification
of
osteomalacia
Abnormal
vitamin D
metabolism
Reduced
availability
Poor diet
Inadequate exposure to sun
Malabsorption
Defective
metabolism
Hepatobiliary disease
Chronic Kidney disease
Vitamin D-dependent rickets type I (AR)
Anticonvulsant drugs, barbiturate, rifamycin → ↑↑
metabolism
Receptor defects Vitamin D-dependent rickets type II (AR)
Altered
phosphate
homeostasis
Malabsorption Malabsorption syndromes
Renal phosphate
loss
X-linked hypophosphatemia (XLD) → Po4 loss
Oncogenic hypophosphatemia→ ↑ FGF-23 → Po4 loss
Fanconi syndrome: loss of Po4, Ca, a.a., sugar...
Defective
mineralization
Aluminum and fluoride toxicity
Bisphosphonate toxicity
Hypophosphatasia
VDDR type I: AR, ↓↓ α-hydroxylase → ↓↓ active vitamin D → treated with calcitriol
VDDR type II: AR, end organ resistance if with alopecia type IIa, if without alopecia type IIb, → treated by
supraphysiological doses of calcitriol & calcium.
Both are called pseudovitaminosis
28. Clinical
features
Osteomalacia is the adult counterpart of rickets
• Skeletal discomfort (from bone and muscle pain),
deformities; kyphosis, triradiate hip i.e., soft hip → this is
exaggerated in children → bone bowing.
• Bone tenderness
• Tetany may be manifested: rarely may be severe enough
→ dysrrhythmia + convulsions
• Muscular weakness with marked proximal myopathy with
waddling gait.
• Rickets: rachitic rosary, Harrison’s groove, delayed
dentition.
30. A- Laboratory
1. Serum Calcium and phosphorus are decreased;
but phosphorus may be increased in renal
failure.
2. Alkaline phosphatase is increased in 90% of
cases.
3. Serum FGF-23 is elevated in many people with
tumour-induced osteomalacia, x-linked
hypophosphatemic rickets.
4. Vitamin D levels (25 OH Vit D) are reduced
5. PTH is often increased
31. Serum 25(OH)D
This is the best test to determine
vitamin D status.
Intestinal calcium absorption is
optimized at levels above 30-32
ng/mL.
PTH start to rise at 25(OH)D < 31
ng/mL, which is another “indirect”
marker of vitamin D insufficiency.
N Engl J Med. 2005 Feb 3. 352(5):515-6; author reply
515-6.
J Am Coll Nutr. 2003 Apr. 22(2):142-6.
J Bone Miner Res. 2003 Jul. 18(7):1342; author reply
1343.
Clin Chem Lab Med. 2016 Jun 30.
Medscape Medical News. May 1, 2013.
32. PTH
• Not always required for the diagnosis of
vitamin D insufficiency but may help to
establish the diagnosis of vitamin D
insufficiency.
• Often, PTH is elevated = 2ry
hyperparathyroidism.
• An inverse relationship exists between PTH
and 25(OH)D levels.
• Usually, PTH levels decrease after the
correction of a vitamin D
Clin Chem Lab Med. 2016 Jun 30.
Indian Journal of Endocrinology and Medicine Page : 422-427, DOI:
10.4103/ijem.IJEM_322_19
33. A- Laboratory
(cont.)
5. Urinary phosphate and low urinary calcium
excretion
6. Levels of 1,25-dihydroxyvitamin D may be
normal and are, therefore, not helpful. If the
serum calcium and 25-hydroxyvitamin D levels
are normal as well, then the defect is likely to
be renal handling of phosphate or end-organ
resistance.
34. Biochemical findings of causes of
osteomalacia
Disorder Ca Po4 ALP 25 (OH) D3 1,25 (OH)2 D3 PTH Other
Vit. D ↓↓ ↓ ↓ ↑ ↓ ↓ ↑
CKD ↓ ↑ ↑ N ↓ ↑ ↓ GFR lead to Po4 retention
VDDR type I ↓ ↓ ↑ N ↓ ↑ As CKD but Po4 is low
VDDR type II ↓ ↓ ↑ N ↑ ↑ End organ resistance
XL-hypophosphatemia
(Vitamin D resistant
rickets)
N ↓ ↑ N N N or ↑ ↑ serum FGF-23 → + heparin
& klotho → bind to PCT →
Po4 loss
Oncogenic
hypophosphatemia
N/↓ ↓ ↑ N ↓ N May have aminoaciduria &
proteinuria, ↑ FGF-23
Phosphate depletion N ↓ ↑ N ↑ N ↑ urine Ca
Fanconi Synd ↓/N ↓ ↑ N ↑ N Aminoaciduria, glucosuria
RTA ↓/N ↓ ↑ N N/↓ N Non-anion gap MA
Toxic
(etidronate/floride)
N N N N N N Dx by biopsy
35. B- Imaging
1. X-ray
Bone rarefaction
Radiographic osteopenia
2. Bone scan: can show multiple
hot spots in the ribs and pelvis
at the site of fractures and the
appearance may be mistaken
for metastases
37. Treatment
1. Treatment of the cause e.g., correct bowel disorder, tumor resection, stop offending
drug.
2. Sun exposure
3. Diet
4. Ca supplements: at doses of 800–1000 mg/day for adults.
5. Vitamin D2 (ergocalciferol), or D3 (cholecalciferol)
6. Alfacalcidol especially in cases of renal failure, vitamin D dependent rickets type I
“physiological dose” i.e., 0.5 – 1 mcg/day, vitamin D dependent rickets type II
“supraphysiological dose”, also in hypophosphatemic rickets.
38. Take Care
• Patients with CKD or hypoparathyroidism need both vitamin
D2 or D3 + calcitriol as CKD → ↓↓ 1α hydroxylase and
hypoparathyroid patients are unable to convert 25 (OH) D to
1,25 (OH)2 D in absence of PTH.
• With rapid clinical improvement, an elevation in serum
25(OH)D and a reduction in PTH.
• Serum ALP levels sometimes rise initially as mineralization of
bone increases, but eventually fall to within the reference
range as the bone disease heals.
42. Statement
regarding
treatment
of vitamin D
deficiency in
adults
It is recommended to initiate a
vitamin D deficiency treatment at a
25(OH)D concentration of <20 ng/mL.
At a concentration of <30 ng/mL a
treatment may be considered
In patients without other risk factors,
a dosage of 6000 IU/day, is
recommended.
Nutrients 2022, 14, 1483.
43. In certain individuals or conditions, higher
vitamin D dosages, up to 10,000 IU
• Malabsorption
• Chronic treatment of medications that influence vitamin
D metabolism
• Obesity
Nutrients 2022, 14, 1483.
44. Duration of treatment
• A treatment duration of 4–12
weeks is recommended
• As soon as a 25(OH)D
concentration of 30–50 ng/mL
is achieved, a maintenance
dose of 800–2000 IU/day is
recommended
Nutrients 2022, 14, 1483.
45. Endocrine society adult dosing
Adults
• 6,000 IU per day or 50,000 IU per week for 8 weeks to achieve a
blood level 25(OH)D above 30 ng/ml. Followed by maintenance
therapy of 1,500-2,000 IU/day.
Special
Cases
• Obese patients, those with malabsorption syndromes, and those
on medications affecting vitamin D metabolism should receive a
higher dose of 6,000 to 10,000 IU/day to achieve levels above 30
ng/ml. Followed by a maintenance dose of 3,000-6,000 IU/day.
The Journal of clinical endocrinology & metabolism. 2011 Jul 1;96(7):1911-30.
46. Route for treatment
• Vitamin D2 or D3 are recommended.
• For the treatment of vitamin D
deficiency in adults, oral
cholecalciferol (vitamin D3) is
preferred.
• In certain risk groups (e.g., patients
with severe malabsorption),
parenteral vitamin D treatment can
be considered.
Mayo Clin Proc 2010; 85:752-758. J Clin Endocrinol Metab 2011; 96:1911-30. Am Fam Phys 2009; 80:841-846. Ann
Intern Med 2015; 162:133-141. Nutrients 2022, 14, 1483.
48. Does it matter if the supplement is taken
on an empty stomach vs with a meal?
• Taking either vitamin D2 or D3 with the largest
meal of the day increased the average serum
25(OH)D level by 50.2%
• Mean serum 25(OH)D concentrations were
higher in those who took the supplement with a
meal that included at least 15 g of fat.
• Oil based preparation may offer this
Cleveland Clinic Journal of Medicine. 2022 Mar;89(3):155.
50. In a nutshell
Goal → 25 (OH) D3 > 30 ng/mL (ideally > 50 ng/mL)
Goal
After replenish → start maintenance vitamin D → 800 – 2000 IU daily of vitamin D
Replenish
Wait for 2 weeks then measure 25 (OH) vitamin D levels
Wait
52. Sun
• Especially between the hours of 10:00 am
and 3:00 pm produces vitamin D = X2
compared with ingested vitamin D.
• If sun exposure produces slight pinkness,
the amount of vitamin D equivalent to
ingesting 10,000-25,000 IU.
• It is affected in increased skin
pigmentation, aging, and application of a
sunscreen.
J Clin Invest. 1993 Jun. 91(6):2552-5.
Am J Clin Nutr. 2008 Apr. 87(4):1080S-6S.
53. The following
foods contain
the indicated
amounts of
vitamin D
(cont.)
• Fortified milk (8 oz) - 100 IU
• Fortified orange juice (8 oz) - 100 IU
• Fortified cereal (1 serving) - 40-80 IU
• Pickled herring (100 g) - 680 IU الرنجة
• Canned salmon with bones (100 g) - 624 IU السلمون
المعلب
• Mackerel (100 g) - 360 IU سمك
الماكريل
• Canned sardines (100 g) - 272 IU المعلب السردين
• Codfish (100 g) - 44 IU
• Swiss cheese (100 g) - 44 IU
• Raw shiitake mushrooms (100 g) - 76 IU
• Most multivitamins (1 tab) - 400 IU
US Department of Agriculture's (USDA's) Nutrient Data Laboratory
54. Vitamin D
Supplement
ation
800–2000 IU/day, in winter times
In elderly: 800–2000 IU/day is
recommended throughout the year
In hospitalized/institutionalized: 800–
2000 IU/day is recommended
throughout the year.
Nutrients 2022, 14, 1483.
55. Vitamin D doses above the UL of 4000 IU/day, are
recommended for prevention in:
Malabsorption, or
using drugs impair
vitamin D
Metabolism
Obesity (BMI ≥ 30
kg/m2)
Dark skin
pigmentation
Nutrients 2022, 14, 1483.
57. Prevention in
childbearing periods
• As recommended for healthy
adults without other risk
factors (800–2000 IU/day).
• The vitamin D
supplementation should be
continued throughout
pregnancy and lactation.
58. The Journal of clinical endocrinology & metabolism. 2011 Jul 1;96(7):1911-30.
59. Prevention: Institute of Medicine (IOM)
Recommendations
Children and
adults aged 1-70:
600 IU per day
Adults older than
70: 800 IU per
day
60. Prevention: AACE Recommendations
Endocr Pract. 2016;22(Suppl 4):1-42.
Daily supplementation with vitamin D3 at a dose of 1,000
to 2,000 IU is typically needed to maintain an optimal
serum 25(OH)D level.
Higher doses may be necessary in the presence of
certain factors including obesity, malabsorption, and
certain ethnicities.
Transplant patients and older individuals may also need
higher doses
61. How…
It is stored in fat, so the frequency of intake (daily, weekly,
monthly) is equal
If monthly doses are not exceedingly high, choose any
Patient preference
For the prevention of vitamin D deficiency, the supplementation
of oral cholecalciferol (vitamin D3) is recommended.
Nutrients 2022, 14, 1483.
65. JAMA. 2021;325(14):1436-1442., Twenty Things Physicians and Patients Should Question. American Society for Clinical Pathology. Published 2017, Clinical Preventive Service Recommendation: vitamin D
deficiency. American Academy of Family Physicians., J Clin Endocrinol Metab. 2011;96(7):1911-1930., Endocr Pract. 2016;22(suppl 4):1-42.
• Neither the Endocrine Society, the Mayo Clinic, the USPSTF, nor the AACE recommends
universal screening for vitamin D deficiency among the general population or asymptomatic
individuals. However, they do recommend screening in individuals with risk factors for vitamin
D deficiency.
• The American Society for Clinical Pathology recommends against it.
67. Screening of vitamin D deficiency should be
considered in
Osteoporosis; Osteomalacia; Musculoskeletal pain;
Chronic kidney disease; Hepatic failure; Malabsorption syndromes (e.g., cystic fibrosis,
inflammatory bowel diseases, bariatric surgery, radiation enteritis);
Hyperparathyroidism;
Chronic treatment with medications that influence vitamin D metabolism (e.g., antiseizure
medications, glucocorticoids, AIDS-medications, antifungal agents, cholestyramine);
Chronic autoimmune diseases (e.g., multiple sclerosis, rheumatoid arthritis);
Nutrients 2022, 14, 1483.
68. Screening of vitamin D deficiency should be
considered in (cont.)
Pregnant and lactating women;
Institutionalized or hospitalized patients;
Older adults (>65 years) in general; Older adults with history of falls or nontraumatic fractures;
Granuloma-forming disorders (e.g., sarcoidosis, tuberculosis, etc.)
BMI ≥ 30kg/m2);
Dark skin pigmentation.
Nutrients 2022, 14, 1483.
70. No conclusive evidence
• Vitamin D has other function rather than the metabolic one
• Remember it is a hormone, so it has roles in cell proliferation,
immune and muscle function, skin differentiation, and reproduction.
• Observational studies “just observational” found that, poor vitamin D
status is present in almost all diseases
• However, RCT, Mendelian randomization and GWAS studies draw
mixed conclusion
There is not yet broad consensus on what constitutes vitamin D deficiency.
Different organizations have slightly different definitions, based on serum levels of 25-hydroxyvitamin D, or 25 (OH)D.
Vitamin D is a fat-soluble vitamin involved in the regulation of calcium homeostasis and bone health. It is synthesized in the body when ultraviolet rays from sunlight strike the skin and trigger vitamin D synthesis.
There are few foods that naturally contain vitamin D or are fortified with it. The major source of vitamin D for both children and adults is exposure to natural sunlight.
The major cause of vitamin D deficiency is lack of sun exposure.
1microgram of vitamin D = 40 International Unit
Pediatrics. 2003 Apr. 111(4 Pt 1):908-10.
Vitamin D deficiency results in abnormalities in calcium, phosphorous, and bone metabolism. Severe and prolonged deficiency can cause bone mineralization diseases, such as rickets in children and osteomalacia in adults.
Vitamin D deficiency has also been associated with fractures, falls, functional limitations, some types of cancer, diabetes, cardiovascular disease, and depression. However the U.S. Preventive Services Task Force notes that, “Inadequate evidence on the benefit of treatment of asymptomatic vitamin D deficiency on other outcomes, including falls, cancer, cardiovascular events, depression, infection, or physical functioning.”
Vitamin D deficiency has also been associated with fractures, falls, functional limitations, some types of cancer, diabetes, cardiovascular disease, and depression. However the U.S. Preventive Services Task Force notes that, “Inadequate evidence on the benefit of treatment of asymptomatic vitamin D deficiency on other outcomes, including falls, cancer, cardiovascular events, depression, infection, or physical functioning.”
Vitamin D deficiency is often asymptomatic. However, severe or prolonged deficiency may cause the following symptoms:
Bone discomfort or pain in the lower back, pelvis, or lower extremities
Falls and impaired physical function
Muscle aches
Proximal muscle weakness
Symmetric low back pain (in women)
The link between vitamin D and bone health cannot be overemphasized
----------------
Vitamin D is important for calcium homeostasis and for optimal skeletal health. The major function of vitamin D is to increase the efficiency of calcium absorption from the small intestine. Heaney and colleagues demonstrated that maximum calcium absorption occurs at levels of 25-hydroxyvitamin D (25[OH]D) greater than 32 ng/mL.
Vitamin D also enhances the absorption of phosphorus from the distal small bowel. Adequate calcium and phosphorus absorption from the intestine is important for proper mineralization of the bone. The second major function of vitamin D is involvement in the maturation of osteoclasts, which resorb calcium from the bones.
The term vitamin D refers to either vitamin D2 or vitamin D3.
Vitamin D3, also known as cholecalciferol, is either made in the skin or obtained in the diet from fatty fish.
Vitamin D2, also known as ergocalciferol, is obtained from irradiated fungi, such as yeast.
Vitamin D2 and vitamin D3 are used to supplement food products or are contained in multivitamins.
Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004 Nov. 89(11):5387-91.
Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998 Oct. 68(4):854-8.
Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008 Mar. 93(3):677-81.
Osteomalacia is characterized by defective bone mineralization, bone pain, muscle weakness and pathological fractures.
There is failure to replace the turnover of Ca and P in bone matrix → bone becomes demineralized, and the bony substance becomes replaced by soft osteoid tissue, so it is mainly a qualitative bone defect.
There is, unlike osteoporosis, a decline in the ratio of mineralized bone to matrix.
Both vitamin D2 (ergocalciferol) from vegetables in the diet, and D3 (cholecalciferol) from animal tissues and de novo synthesis in skin, are metabolized in the liver to 25-hydroxyvitamin D and then in the kidney to 1,25-dihydroxyvitamin D3.
The latter affects calcium metabolism by acting on the parathyroid glands (negative-feedback loop on PTH stimulation of renal vitamin D hydroxylases), GI tract (increased absorption of calcium and phosphate), and bone (both bone resorption and osteoblast activation with bone formation). Kidneys; increase reabsorption of phosphate.
------------------
Vitamin D obtained from sun exposure, foods, and supplements is biologically inert and must undergo two hydroxylations in the body for activation. The first hydroxylation, which occurs in the liver, converts vitamin D to 25-hydroxyvitamin D [25(OH)D], also known as “calcidiol.” The second hydroxylation occurs primarily in the kidney and forms the physiologically active 1,25-dihydroxyvitamin D [1,25(OH)2D], also known as “calcitriol”
The most common cause is vitamin D deficiency, the low levels of vitamin D causes a reduction of calcium absorption from the intestine.
The low calcium absorption stimulates parathyroid hormone secretion which restores serum calcium levels towards normal 1by increasing bone resorption and 2renal tubular calcium reabsorption. The level of parathyroid hormone also 3promotes phosphaturia and causes phosphate depletion.
It is the combination of calcium loss from bone and phosphate depletion that leads to impaired bone mineralization.
This is the best test to determine vitamin D status.
The circulating half-life of 25(OH)D is 2 weeks.
A 25(OH)D level of less than 30 ng/mL is considered vitamin D insufficient.
A 25(OH)D level of less than 15 or 20 ng/mL have been used to define vitamin D deficiency.
Intestinal calcium absorption is optimized at levels above 30-32 ng/mL.
Parathyroid hormone levels start to rise at 25(OH)D levels below 31 ng/mL, which is another marker of vitamin D insufficiency.
--------------------
N Engl J Med. 2005 Feb 3. 352(5):515-6; author reply 515-6.
J Am Coll Nutr. 2003 Apr. 22(2):142-6.
J Bone Miner Res. 2003 Jul. 18(7):1342; author reply 1343.
Clin Chem Lab Med. 2016 Jun 30.
Medscape Medical News. May 1, 2013.
Vitamin D requirements may vary by individual, and there is no one 25(OH)D level that defines deficiency for all individuals.
Total 25(OH)D levels are currently considered the best marker of vitamin D status; however, levels are difficult to measure accurately.
Evidence suggests that results vary by testing method and between laboratories using the same testing methods
-----------------------------
A 25(OH)D concentration of <20 ng/mL (<50 nmol/L) is considered as vitamin D deficiency
A 25(OH)D concentration of ≥20 ng/mL (≥50 nmol/L) and <30 ng/mL (<75 nmol/L) is considered as vitamin D insufficiency
A 25(OH)D concentration of 30–50 ng/mL (75–125 nmol/L) is considered as vitamin D sufficiency
A 25(OH)D concentration of >50–60 ng/mL (125–150 nmol/L) is considered as safe but not as a target level
A 25(OH)D concentration of >60–100 ng/mL (150–250 nmol/L) is considered as area of uncertainty with potential benefits or risks.
A 25(OH)D concentration of >100 ng/mL (250 nmol/L) is considered as oversupply/vitamin D toxicity
Although not always required for the diagnosis of vitamin D insufficiency, a serum PTH may be used to help establish the diagnosis of vitamin D insufficiency.
Often, patients with vitamin D insufficiency have a corresponding elevated PTH, indicating secondary hyperparathyroidism.
An inverse relationship exists between PTH and 25(OH)D levels.
Usually, PTH levels decrease after the correction of a vitamin D insufficiency.
If doubt remains as to the diagnosis of osteomalacia, a transiliac bone biopsy can be taken.
Tetracycline-labelled bone biopsy is the gold standard diagnostic test.
It is recommended to initiate a vitamin D deficiency treatment at a 25(OH)D concentration of <20 ng/mL (<50 nmol/L).
At a concentration of <30 ng/mL (<75 nmol/L) a treatment may be considered
As initial dose for the treatment of vitamin D deficiency in patients without other risk factors, a dosage of 6000 IU, equivalent to a daily dosage, is recommended.
A treatment duration of 4–12 weeks is recommended, depending on the severity of vitamin D deficiency.
As soon as a 25(OH)D concentration of 30–50 ng/mL (75–125 nmol/L) is achieved, a maintenance dose of 800–2000 IU/day is recommended, that can also be used as an initial treatment dose if there is no requirement for a rapid correction of vitamin D deficiency.
There is broad consensus that increased intake of dietary vitamin D is not enough to correct deficiency. Vitamin D supplementation is required. Vitamin D2 or D3 are recommended.
For the treatment of vitamin D deficiency in adults, oral cholecalciferol (vitamin D3) is preferred.
In certain risk groups (e.g., patients with severe malabsorption), parenteral vitamin D treatment can be considered.
In a small study, Mulligan and Licata found that taking either vitamin D2 or D3 with the largest meal of the day increased the average serum 25(OH)D level by 50.2% (± 13.4%).
Mean serum 25(OH)D concentrations were higher in those who took the supplement with a meal that included at least 15 g of fat.
Sensible sun exposure, especially between the hours of 10:00 am and 3:00 pm produces vitamin D in the skin that may last twice as long in the blood compared with ingested vitamin D.
If sun exposure produces slight pinkness, the amount of vitamin D produced in response to exposure of the full body is equivalent to ingesting 10,000-25,000 IU.
A variety of factors reduce the skin’s vitamin D-3 production, including increased skin pigmentation, aging, and the topical application of a sunscreen.
Foods thought to contain high amounts of vitamin D3 are oily fish, such as salmon, mackerel, and blue fish, as well as fortified milk and other dairy products.
A single serving (3.5 oz) of wild-caught salmon has 988 ± 524 IU of vitamin D3, an amount that remains unchanged after baking but that decreases by 50% if the salmon is fried in vegetable oil.
In comparison, farm-raised salmon has only 25% of the vitamin D3 content found in the flesh of wild salmon. Blue fish and mackerel have vitamin D3 levels of 280 ± 68 IU and 24 IU, respectively.
In healthy adults without other risk factors, a supplementation of 800–2000 IU/day, for those who want to achieve a targeted/measured 25(OH)D concentration, should be considered during wintertime (mainly November-April) due to insufficient endogenous dermal vitamin D synthesis and depending on the body weight
Due to decreased skin synthesis in elderly (>65 years), a supplementation of 800–2000 IU/day is recommended throughout the year.
In hospitalized/institutionalized individuals, a supplementation of 800–2000 IU/day is recommended throughout the year.
Vitamin D doses above the UL of 4000 IU/day, are recommended for prevention compared to healthy adults without other risk factors
Women planning a pregnancy should start or maintain the vitamin D supplementation as recommended for healthy adults without other risk factors (800–2000 IU/day).
The vitamin D supplementation should be continued throughout pregnancy and lactation.
Daily supplementation with vitamin D3 at a dose of 1,000 to 2,000 IU is typically needed to maintain an optimal serum 25(OH)D level.
Higher doses may be necessary in the presence of certain factors including obesity, malabsorption, and certain ethnicities. Transplant patients and older individuals may also need higher doses
As vitamin D metabolites are stored in fat and other tissues and gradually released into the blood circulation, a daily or weekly or monthly supplementation regimen is equally effective and safe, if monthly doses are not exceedingly high, for the prevention of vitamin D deficiency.
A tailored approach for vitamin D administration, involving the patients’ preferences of the supplementation regimen (daily, weekly, monthly) might enhance the adherence to preventive vitamin D supplementation.
For the prevention of vitamin D deficiency, the supplementation of oral cholecalciferol (vitamin D3) is recommended.
The United States Preventive Services Task Force is "an independent panel of experts in primary care and prevention that systematically reviews the evidence of effectiveness and develops recommendations for clinical preventive services“
No organization recommends population-based screening for vitamin D deficiency, and the American Society for Clinical Pathology recommends against it.
The American Academy of Family Physicians supports the USPSTF 2014 recommendation, which states that there is insufficient evidence to recommend screening the general population for vitamin D deficiency.
The Endocrine Society and the American Association of Clinical Endocrinologists recommend screening for vitamin D deficiency in individuals at risk.
The Endocrine Society does not recommend population screening for vitamin D deficiency in individuals not at risk.
Neither the Endocrine Society, the Mayo Clinic, the U.S. Preventive Services Task Force, nor the American Association of Clinical Endocrinologists recommends universal screening for vitamin D deficiency among the general population or asymptomatic individuals. However, they do recommend screening in individuals with risk factors for vitamin D deficiency.
As strongly suggested by genetic, molecular, cellular, and animal studies, extraskeletal effects related to vitamin D signaling include roles in cell proliferation, immune and muscle function, skin differentiation, and reproduction, with vitamin D having vascular and metabolic actions as well.
Observational studies have pointed to a relationship between poor vitamin D status and almost all diseases connected to these extraskeletal influences.
However, while randomized, controlled trials and Mendelian randomization studies have indicated that vitamin D supplementation can lower the incidence of some disorders, only mixed conclusions on the matter have been reached globally.